CN101389768B - 作为疾病的生物标志的生脂腺病毒 - Google Patents

作为疾病的生物标志的生脂腺病毒 Download PDF

Info

Publication number
CN101389768B
CN101389768B CN200680053371.XA CN200680053371A CN101389768B CN 101389768 B CN101389768 B CN 101389768B CN 200680053371 A CN200680053371 A CN 200680053371A CN 101389768 B CN101389768 B CN 101389768B
Authority
CN
China
Prior art keywords
cancer
virus
subject
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680053371.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101389768A (zh
Inventor
R·L·阿特金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obetech LLC
Original Assignee
Obetech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obetech LLC filed Critical Obetech LLC
Publication of CN101389768A publication Critical patent/CN101389768A/zh
Application granted granted Critical
Publication of CN101389768B publication Critical patent/CN101389768B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
CN200680053371.XA 2005-12-27 2006-12-27 作为疾病的生物标志的生脂腺病毒 Expired - Fee Related CN101389768B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75340205P 2005-12-27 2005-12-27
US60/753,402 2005-12-27
PCT/US2006/062632 WO2007120362A2 (en) 2005-12-27 2006-12-27 Adipogenic adenoviruses as a biomarker for disease

Publications (2)

Publication Number Publication Date
CN101389768A CN101389768A (zh) 2009-03-18
CN101389768B true CN101389768B (zh) 2015-11-25

Family

ID=38610014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680053371.XA Expired - Fee Related CN101389768B (zh) 2005-12-27 2006-12-27 作为疾病的生物标志的生脂腺病毒

Country Status (11)

Country Link
US (5) US7442511B2 (cg-RX-API-DMAC7.html)
EP (2) EP1977009B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009521707A (cg-RX-API-DMAC7.html)
KR (1) KR20080114683A (cg-RX-API-DMAC7.html)
CN (1) CN101389768B (cg-RX-API-DMAC7.html)
AU (1) AU2006342053A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0620755A2 (cg-RX-API-DMAC7.html)
CA (1) CA2635269A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008008453A (cg-RX-API-DMAC7.html)
RU (1) RU2008130893A (cg-RX-API-DMAC7.html)
WO (1) WO2007120362A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507418B2 (en) * 2005-09-09 2009-03-24 Obetech, Llc Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
CA2635269A1 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
JP2009156254A (ja) * 2007-12-05 2009-07-16 Ibiden Co Ltd 排気ガス処理体の保持シール部材及び排気ガス処理装置
KR101208778B1 (ko) 2008-03-03 2012-12-05 노파르티스 아게 Ｔｌｒ 활성 조정제로서의 화합물 및 조성물
WO2010011440A2 (en) * 2008-06-16 2010-01-28 Obetech Llc Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
WO2011050299A2 (en) * 2009-10-22 2011-04-28 Obetech Llc Adenovirus infection in animals
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8585588B2 (en) 2009-11-18 2013-11-19 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
US20130052635A1 (en) * 2010-03-25 2013-02-28 Richard L. Atkinson Method For Detecting Lipogenic Adenovirus
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012006512A1 (en) * 2010-07-08 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
US20130178517A1 (en) * 2010-07-09 2013-07-11 Richard L. Atkinson Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
WO2016073773A1 (en) 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
DK3752182T3 (da) 2018-02-12 2024-08-12 Inimmune Corp Toll-like receptor ligands
EP3861348A4 (en) * 2018-10-05 2022-07-20 Minomic International Ltd. BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER
EP4240843A1 (en) 2020-11-04 2023-09-13 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386800T1 (de) * 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
WO1998044946A1 (en) 1997-04-04 1998-10-15 Obetech, Llc Viral obesity methods and compositions
JP2000072800A (ja) * 1998-08-26 2000-03-07 Toagosei Co Ltd 抗アデノウイルス３７型モノクローナル抗体及びその用途
US8008436B2 (en) * 2005-11-30 2011-08-30 Wayne State Univeristy Adenovirus 36 E4 orf 1 gene and protein and their uses
CA2635269A1 (en) * 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Vangipuram Sharada D et al.A human adenovirus enhances preadipocyte differentiation.《Obesity Research》.2004,第12卷(第5期),770-777. *
Winters W D et al.Incomplete human adenovirus replication in canine tumour cells and serological evidence of infections in tumour-bearing canine pets.《J. Comp.Path》.1980,第90卷(第2期),197-207. *

Also Published As

Publication number Publication date
US20070218081A1 (en) 2007-09-20
EP1977009B1 (en) 2016-08-17
US20090087455A1 (en) 2009-04-02
US20110189235A1 (en) 2011-08-04
WO2007120362A3 (en) 2008-08-14
US7442511B2 (en) 2008-10-28
EP1977009A4 (en) 2009-06-03
US20090087833A1 (en) 2009-04-02
CA2635269A1 (en) 2007-10-25
US7910310B2 (en) 2011-03-22
RU2008130893A (ru) 2010-02-10
US20130323273A1 (en) 2013-12-05
WO2007120362A2 (en) 2007-10-25
EP1977009A2 (en) 2008-10-08
AU2006342053A1 (en) 2007-10-25
KR20080114683A (ko) 2008-12-31
CN101389768A (zh) 2009-03-18
BRPI0620755A2 (pt) 2011-11-22
JP2009521707A (ja) 2009-06-04
EP2390372A1 (en) 2011-11-30
MX2008008453A (es) 2008-11-28
US7745110B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
CN101389768B (zh) 作为疾病的生物标志的生脂腺病毒
USRE42129E1 (en) Viral obesity methods and compositions
CN112266983B (zh) 一种用于检测人乳头瘤病毒hpv16和hpv18的探针组及其试剂盒
US8227586B2 (en) Human polyomavirus, designated the wu virus, obtained from human respiratory secretions
US20090220946A1 (en) Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
CN101153059A (zh) 用于鼻咽癌筛查、诊断和治疗效果预测的elisa试剂盒
Yoshida et al. Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan
JP2002515725A (ja) カポジ肉腫および腹膜後繊維腫症に関連するガンマヘルペスウイルスのｄｎａポリメラーゼ
WO2010011440A2 (en) Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
KR100785397B1 (ko) 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
CN110073219B (zh) 用于对hpv16阳性癌的治疗控制的血清学测试
CN100479858C (zh) 一种重组痘苗-sars疫苗及其制备方法
CN108754030A (zh) 一种人ki多瘤病毒的荧光定量pcr引物和探针及其应用
KR100888793B1 (ko) 사스 코로나바이러스의 재조합 뉴클레오캡시드 단백질 및이것의 용도
JP3113321B2 (ja) エプスタインバーウイルスの検出方法
CN119775402A (zh) 一种抗新型布尼亚病毒np蛋白的单克隆抗体及其制备方法和应用
CN116790672A (zh) 一种靶向结肠癌的重组腺相关病毒的构建方法及其应用
CN112195281A (zh) 一种用于检测人乳头瘤病毒hpv56的探针及其试剂盒
WO2006079290A1 (en) A recombinant sars-cov vaccine comprising attenuated vaccinia virus carriers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20181227